These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

209 related articles for article (PubMed ID: 35257066)

  • 1. Germline Mutations for Kidney Volume in ADPKD.
    Kataoka H; Yoshida R; Iwasa N; Sato M; Manabe S; Kawachi K; Makabe S; Akihisa T; Ushio Y; Teraoka A; Tsuchiya K; Nitta K; Mochizuki T
    Kidney Int Rep; 2022 Mar; 7(3):537-546. PubMed ID: 35257066
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prediction of Renal Prognosis in Patients with Autosomal Dominant Polycystic Kidney Disease Using PKD1/PKD2 Mutations.
    Kataoka H; Fukuoka H; Makabe S; Yoshida R; Teraoka A; Ushio Y; Akihisa T; Manabe S; Sato M; Mitobe M; Tsuchiya K; Nitta K; Mochizuki T
    J Clin Med; 2020 Jan; 9(1):. PubMed ID: 31948117
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Patients with Protein-Truncating
    Lanktree MB; Guiard E; Akbari P; Pourafkari M; Iliuta IA; Ahmed S; Haghighi A; He N; Song X; Paterson AD; Khalili K; Pei YPC
    Clin J Am Soc Nephrol; 2021 Mar; 16(3):374-383. PubMed ID: 33602752
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Predicting liver cyst severity by mutations in patients with autosomal-dominant polycystic kidney disease.
    Kataoka H; Watanabe S; Sato M; Manabe S; Makabe S; Akihisa T; Ushio Y; Iwasa N; Yoshida R; Tsuchiya K; Nitta K; Mochizuki T
    Hepatol Int; 2021 Jun; 15(3):791-803. PubMed ID: 33811288
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Venglustat, a Novel Glucosylceramide Synthase Inhibitor, in Patients at Risk of Rapidly Progressing ADPKD: Primary Results of a Double-Blind, Placebo-Controlled, Phase 2/3 Randomized Clinical Trial.
    Gansevoort RT; Hariri A; Minini P; Ahn C; Chapman AB; Horie S; Knebelmann B; Mrug M; Ong ACM; Pei YPC; Torres VE; Modur V; Antonshchuk I; Perrone RD
    Am J Kidney Dis; 2023 May; 81(5):517-527.e1. PubMed ID: 36535535
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparative analysis of tools to predict rapid progression in autosomal dominant polycystic kidney disease.
    Naranjo J; Furlano M; Torres F; Hernandez J; Pybus M; Ejarque L; Cordoba C; Guirado L; Ars E; Torra R
    Clin Kidney J; 2022 May; 15(5):912-921. PubMed ID: 35498884
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effect of tolvaptan on renal involvement in patients with autosomal dominant polycystic kidney disease according to different gene mutations.
    Moriyama T; Nakayama Y; Soejima M; Yokota Y; Ota K; Ito S; Kodama G; Nakamura N; Kurokawa Y; Yano J; Ueda U; Takamiya Y; Kaida Y; Hazama T; Shibata R; Koda Y; Fukami K
    Clin Exp Nephrol; 2021 Mar; 25(3):251-260. PubMed ID: 33141305
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Accuracy and processing time of kidney volume measurement methods in rodents polycystic kidney disease models: superiority of semiautomated kidney segmentation.
    Doss MC; Mullen S; Roye R; Zhou J; Chumley P; Mrug E; Wallace DP; Qian F; Harris PC; Yoder BK; Kim H; Mrug M
    Am J Physiol Renal Physiol; 2023 Apr; 324(4):F423-F430. PubMed ID: 36794756
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Predicted Mutation Strength of Nontruncating PKD1 Mutations Aids Genotype-Phenotype Correlations in Autosomal Dominant Polycystic Kidney Disease.
    Heyer CM; Sundsbak JL; Abebe KZ; Chapman AB; Torres VE; Grantham JJ; Bae KT; Schrier RW; Perrone RD; Braun WE; Steinman TI; Mrug M; Yu AS; Brosnahan G; Hopp K; Irazabal MV; Bennett WM; Flessner MF; Moore CG; Landsittel D; Harris PC;
    J Am Soc Nephrol; 2016 Sep; 27(9):2872-84. PubMed ID: 26823553
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prognostic enrichment design in clinical trials for autosomal dominant polycystic kidney disease: the HALT-PKD clinical trial.
    Irazabal MV; Abebe KZ; Bae KT; Perrone RD; Chapman AB; Schrier RW; Yu AS; Braun WE; Steinman TI; Harris PC; Flessner MF; Torres VE;
    Nephrol Dial Transplant; 2017 Nov; 32(11):1857-1865. PubMed ID: 27484667
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pancreatic Cysts in Autosomal Dominant Polycystic Kidney Disease: Prevalence and Association with PKD2 Gene Mutations.
    Kim JA; Blumenfeld JD; Chhabra S; Dutruel SP; Thimmappa ND; Bobb WO; Donahue S; Rennert HE; Tan AY; Giambrone AE; Prince MR
    Radiology; 2016 Sep; 280(3):762-70. PubMed ID: 27046073
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The Clinical Manifestation and Management of Autosomal Dominant Polycystic Kidney Disease in China.
    Xue C; Zhou CC; Wu M; Mei CL
    Kidney Dis (Basel); 2016 Oct; 2(3):111-119. PubMed ID: 27921038
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Genetics May Predict Effectiveness of Tolvaptan in Autosomal Dominant Polycystic Kidney Disease.
    Sekine A; Hoshino J; Fujimaru T; Suwabe T; Mizuno H; Kawada M; Hiramatsu R; Hasegawa E; Yamanouchi M; Hayami N; Mandai S; Chiga M; Kikuchi H; Ando F; Mori T; Sohara E; Uchida S; Sawa N; Takaichi K; Ubara Y
    Am J Nephrol; 2020; 51(9):745-751. PubMed ID: 32784291
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A novel PKD1 variant demonstrates a disease-modifying role in trans with a truncating PKD1 mutation in patients with autosomal dominant polycystic kidney disease.
    Ali H; Hussain N; Naim M; Zayed M; Al-Mulla F; Kehinde EO; Seaburg LM; Sundsbak JL; Harris PC
    BMC Nephrol; 2015 Mar; 16():26. PubMed ID: 25880449
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prognostic Enrichment Design in Clinical Trials for Autosomal Dominant Polycystic Kidney Disease: The TEMPO 3:4 Clinical Trial.
    Irazabal MV; Blais JD; Perrone RD; Gansevoort RT; Chapman AB; Devuyst O; Higashihara E; Harris PC; Zhou W; Ouyang J; Czerwiec FS; Torres VE
    Kidney Int Rep; 2016 Nov; 1(4):213-220. PubMed ID: 29142926
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Mutational Screening of PKD1 and PKD2 Genes in Iranian Population Diagnosed with Autosomal Dominant Polycystic Kidney Disease.
    Ranjzad F; Tara A; Basiri A; Aghdami N; Moghadasali R
    Clin Lab; 2017 Jul; 63(7):1261-1267. PubMed ID: 28792715
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Predicting Future Renal Function Decline in Patients with Autosomal Dominant Polycystic Kidney Disease Using Mayo Clinic Classification.
    Borrego Utiel FJ; Esteban de la Rosa RJ; Merino García E; Medina Benítez A; Polo Moyano A; Moriana Domínguez C; Morales García AI; Bravo Soto JA
    Am J Nephrol; 2021; 52(8):630-641. PubMed ID: 34518464
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Assessing Risk of Rapid Progression in Autosomal Dominant Polycystic Kidney Disease and Special Considerations for Disease-Modifying Therapy.
    Chebib FT; Torres VE
    Am J Kidney Dis; 2021 Aug; 78(2):282-292. PubMed ID: 33705818
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [ADPKD: predictors of Renal Disease progression].
    Scolari F; Dallera N; Saletti A; Terlizzi V; Izzi C
    G Ital Nefrol; 2016; 33(5):. PubMed ID: 27796018
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Age- and height-adjusted total kidney volume growth rate in autosomal dominant polycystic kidney diseases.
    Higashihara E; Yamamoto K; Kaname S; Okegawa T; Tanbo M; Yamaguchi T; Shigemori K; Miyazaki I; Yokoyama K; Nutahara K
    Clin Exp Nephrol; 2019 Jan; 23(1):100-111. PubMed ID: 30097754
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.